In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- Alpha Beta T-cell and B-cell depleted allogeneic transplantation followed by Blinatumomab therapy for high-risk B-Acute Lymphoblastic Leukemia pilot study
- Blinatumomab bridging therapy in high-risk B-ALL clinical trial
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Cancer Clinical Trials - COG-ACCL1333
Protocol Summary
- Protocol No
- COG-ACCL1333
- Principal Investigator
- Paul Harker-Murray
- Phase
- III
- Title
- A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-Asparaginase
- Associated Disease(s)
-
Late Effects and Supportive Studies
- Description (Summary)
- The main purpose of this research study is to compare the thromboembolic prevention of Apixaban vs no prophylactic anticoagulant during induction chemotherapy in those receiving (PEG)L-Asparaginase.
- Participating Institutions
- Childrens Hospital of Wisconsin
- ClinicalTrials.gov
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
